Catalyst Wire Dossier Catalyst Wire Dossier

insulin peglispro (LY2605541)

insulin peglispro · Eli Lilly and Company
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for insulin peglispro (LY2605541), covering 2019-03-01 to 2019-03-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics [Phase 1]

See pricing